Harmony Biosciences Completes Enrollment Of Phase 3 Registrational Intune Study In Idiopathic Hypersomnia
Portfolio Pulse from Happy Mohamed
Harmony Biosciences (NASDAQ:HRMY) has completed enrollment for its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH) nine months ahead of schedule. Topline results are expected in Q4 2023.
May 25, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences has completed enrollment for its Phase 3 INTUNE study on pitolisant for idiopathic hypersomnia ahead of schedule, with topline results expected in Q4 2023.
The early completion of enrollment for the Phase 3 INTUNE study indicates strong interest and momentum in Harmony Biosciences' pitolisant development program. This may positively impact HRMY's stock price in the short term as it demonstrates progress in their clinical trials and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100